Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
…, N Damjanov, M Gupta, Y Karino, M Karwal… - The Lancet …, 2018 - thelancet.com
Background Immune checkpoint blockade therapy has shown promising results in patients
with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of …
with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of …
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo …
…, R Jochim, A Jones, M Just, A Kallab, M Karwal… - The Lancet …, 2020 - thelancet.com
Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab,
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …
Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
Purpose: Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling,
has demonstrated encouraging antitumor activity in preclinical and phase I studies. We …
has demonstrated encouraging antitumor activity in preclinical and phase I studies. We …
Pembrolizumab monotherapy for previously untreated advanced hepatocellular carcinoma: data from the open-label, phase II KEYNOTE-224 trial
G Verset, I Borbath, M Karwal, C Verslype… - Clinical cancer …, 2022 - AACR
… Karwal reports grants from Merck during the conduct of the study; and personal fees from
Eisai … This article must therefore be hereby marked advertisement in accordance with 18 USC …
Eisai … This article must therefore be hereby marked advertisement in accordance with 18 USC …
[PDF][PDF] FDG-PET appearance of pelvic Castleman's disease
SP Murphy, MA Nathan, MW Karwal - Journal of Nuclear Medicine, 1997 - Soc Nuclear Med
We report a case of Castleman's disease demonstrating 18F-fluorodeoxyglucose (FDG)
localization by whole-body PET imaging in a pelvic soft-tissue mass shown on abdominopelvic …
localization by whole-body PET imaging in a pelvic soft-tissue mass shown on abdominopelvic …
Tracheobronchial amyloidosis: a surgical disease with long-term consequences
KA Dahl, KH Kernstine, TL Vannatta, MW Karwal… - The Journal of thoracic …, 2004 - jtcvs.org
Amyloidosis results from abnormal protein deposition and accumulation in extracellular spaces.
1 The multi-ple distinct forms of this disease have heterogeneous clinical manifestations …
1 The multi-ple distinct forms of this disease have heterogeneous clinical manifestations …
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors
…, T Carlisle, P Zehr, M Connolly, M Karwal… - Journal of Nuclear …, 2003 - Soc Nuclear Med
Because of the presence of cell membrane somatostatin receptors (SSTRs), many
neuroendocrine tumors will bind analogs of somatostatin. Y-Dodecanetetraacetic acid-Phe1-Tyr3-…
neuroendocrine tumors will bind analogs of somatostatin. Y-Dodecanetetraacetic acid-Phe1-Tyr3-…
[HTML][HTML] Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study
…, J Maher, X Lie, C Gwaltney, A Barzi, M Karwal… - Quality of life …, 2022 - Springer
Purpose This study aimed to elucidate the patient experience of hepatocellular carcinoma (HCC)
to guide patient-centered outcome measurement in drug development. Methods …
to guide patient-centered outcome measurement in drug development. Methods …
Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487 [OctreoTher™]) treatment
…, M Connolly, S O'Dorisio, M Karwal… - Cancer Biotherapy …, 2004 - liebertpub.com
Y-90-DOTA-Phe1-Tyr3-Octreotide ( 90 Y-SMT 487, OctreoTher™) has shown potential for
effectively treating patients with neuroendocrine tumors. The dose-limiting organ for this agent …
effectively treating patients with neuroendocrine tumors. The dose-limiting organ for this agent …
A pilot study of preoperative vandetanib on markers of proliferation and apoptosis in breast cancer
…, LM Erdahl, SL Sugg, MW Karwal… - American journal of …, 2021 - journals.lww.com
Methods: Patients with invasive breast cancer were randomly assigned vandetanib 300 mg
or placebo PO daily for 2 weeks before operative resection from January 2014 to June 2017. …
or placebo PO daily for 2 weeks before operative resection from January 2014 to June 2017. …